Singapore, July 28 -- US-based startup Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumours, has announced the signing of a Memorandum of Understanding (MoU) with the National Cancer Centre Singapore (NCCS).

The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma.

As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, includi...